interleukin-11


Also found in: Dictionary, Thesaurus, Encyclopedia.
Related to interleukin-11: IL-13, Oprelvekin, IL-3, Interleukin 12, Neumega

in·ter·leu·kin-11

(in'tĕr-lū'kin),
A cytokine and growth factor derived from bone marrow stromal cells (endothelial cells, macrophages, and preadipocytes) that stimulates increased plasma concentrations of acute-phase proteins and is a growth factor with multiple hematopoietic effects.

interleukin-11 (IL-11)

a cytokine produced by bone marrow stromal cells. It induces IL-6-dependent murine plasmacytoma cells to proliferate and plays an important role in early platelet hematopoiesis.

IL11

A gene on chromosome 19q13.3-q13.4 that encodes interleukin-11, a member of the gp130 family of cytokines, which drive the assembly of multi-subunit receptor complexes, all of which contain at least one molecule of the transmembrane signalling receptor IL6ST. IL11 directly stimulates the proliferation of haematopoietic stem cells and megakaryocyte progenitor cells, and it induces megakaryocyte maturation resulting in increased platelet production.

in·ter·leu·kin-11

(in'tĕr-lū'kin)
A cytokine derived from bone marrow stromal cells (endothelial cells, macrophages, and preadipocytes) that stimulates increased plasma concentrations of acute phase proteins.

interleukin-11

A CYTOKINE produced by bone marrow stromal cells that promotes the induction of ACUTE PHASE PROTEINS.
References in periodicals archive ?
Polymorphisms in the interleukin-11 receptor gene are associated with bone mineral density and body mass index in Spanish postmenopausal women.
Association of the G-174C variant in the interleukin-11 promoter region with bone loss and fracture risk in older women.
A functional polymorphic variant in the interleukin-11 gene promoter associated with low bone resorption in postmenopausal women.
Cytokine and hormonal stimulation of human osteosarcoma interleukin-11 production.
Transforming growth factor-beta stimulates interleukin-11 transcription via complex activating protein-1-dependent pathways.
Although interleukin-11 has interesting therapeutic properties, Schering-Plough has made a strategic decision to focus development efforts on interleukin-4 (IL-4) and interleukin-10 (IL-10), both of which are products of Schering-Plough's internal research program and currently in clinical testing," said Jonathan R.